Introduction
Molecular targeted cancer therapies are the biggest and fastest
growing class of cancer drugs in terms of sales. As growth of
revenues from cytotoxic therapies and antihormonal therapies has
slowed and many key brands in these classes face imminent patent
expiries, it is unsurprising that the major oncology companies
have shifted their focus towards the molecular targeted cancer
therapies market.
Reasons to Purchase
- Quantify the performance of each of the marketed molecular
targeted cancer therapies in the seven major markets over the
period 2008 to 2018
- Assess the changing key opportunities and threats both for
currently marketed and pipeline targeted therapy cancer brands
- Identify the leading brands in this market over the next 10
years and understand the key factors driving their success
